Novo pumps $97.1M into Danish bioproduction startup 21st.BIOnews2021-12-21T14:05:28+00:00December 21st, 2021|Fierce Pharma|
Acadia slims Nuplazid label expansion bid in hopes of clinching Alzheimer’s dementia nod without extra studiesnews2021-12-21T13:54:17+00:00December 21st, 2021|Fierce Pharma|
Iacta bags rights to Tallc’s pan-ocular drug delivery technologynews2021-12-21T13:39:09+00:00December 21st, 2021|Fierce Pharma|
BARDA, in ‘Beyond the Needle’ DRIVe, backs IDRI to develop nasal RNA vaccine against pandemic flunews2021-12-21T13:35:17+00:00December 21st, 2021|Fierce Pharma|
Candel enlists Bionauts for fight against brain cancers, setting stage for delivery of oncolytic viruses using tiny robotsnews2021-12-21T13:32:10+00:00December 21st, 2021|Fierce Pharma|
Editor’s corner: The top 10 Fierce Pharma Marketing stories of 2021 recappednews2021-12-21T12:32:46+00:00December 21st, 2021|Fierce Pharma|
Novartis wins belated Leqvio FDA approval, with a plan to avoid the pitfalls of earlier PCSK9 cholesterol drugsnews2021-12-21T10:48:24+00:00December 21st, 2021|Fierce Pharma|
Novartis aims to avoid pitfalls of earlier PCSK9 launches with its new blockbuster hopeful Leqvionews2021-12-21T10:48:24+00:00December 21st, 2021|Fierce Pharma|
2022 forecast: With omicron extending the pandemic, how will biopharma respond to COVID?news2021-12-21T02:28:01+00:00December 21st, 2021|Fierce Pharma|
Intra-Cellular scores another FDA nod for Caplyta, this time for bipolar disordernews2021-12-20T20:54:51+00:00December 20th, 2021|Fierce Pharma|
